Page 144 - 2020_07-Haematologica-web

R. Aplenc et al. 58(1):13-23.
13. Niewerth D, Franke NE, Jansen G, et al. Higher ratio immune versus constitutive proteasome level as novel indicator of sen- sitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013;98(12):1896-1904.
14. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myel- ogenous leukemia. Clin Cancer Res. 2008; 14(5):1446-1454.
15. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25): 6025-6031.
16. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal dox- orubicin in patients with advanced hema- tologic malignancies. Blood. 2005; 105(8):3058-3065.
17. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor borte- zomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007;13(5):1516- 1522.
18. Horton TM, Perentesis JP, Gamis AS, et al. A Phase 2 study of bortezomib combined
with either idarubicin/cytarabine or cytara- bine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood Cancer. 2014;61(10):1754-1760.
19. Aplenc R, Alonzo TA, Gerbing RB, et al. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2006; 108(1):74-80.
20. Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsoli- dation therapy does not prevent relapse in children with AML: results from NOPHO- AML 2004. Blood. 2012;120(5):978-984.
leukemia: a Children’s Oncology Group report. J Clin Oncol. 2017; 35(15_suppl): 10515-10515.
24. Getz KD, Sung L, Leger K, et al. Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Children’s Oncology Group report. J Clin Oncol. 2018; 36(15_suppl):10501-10501.
25. Hoff FW, Qiu Y, Hu W, et al. Abstract 451: Proteomic profiling of the unfolded protein response identifies patients benefiting from bortezomib in pediatric acute myeloid leukemia. Cancer Res. 2018;78(Suppl 13):451.
26. Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent struc- tural alterations and age-specific mutation- al interactions. Nat Med. 2018;24(1):103-
21. Creutzig U, Zimmermann M, Bourquin JP,
et al. Randomized trial comparing liposo-
mal daunorubicin with idarubicin as induc-
tion for pediatric acute myeloid leukemia:
results from Study AML-BFM 2004. Blood. 112.
2013;122(1):37-43.
22. Tsukimoto I, Tawa A, Horibe K, et al. Risk-
stratified therapy and the intensive use of cytarabine improves the outcome in child- hood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-4013.
23. Getz KD, Alonzo TA, Sung L, et al. Four versus five chemotherapy courses in patients with low risk acute myeloid
27. Miller TP, Li Y, Getz KD, et al. Using elec- tronic medical record data to report labora- tory adverse events. Br J Haematol. 2017; 177(2):283-286.
28. Miller TP, Troxel AB, Li Y, et al. Comparison of administrative/billing data to expected protocol-mandated chemother- apy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood Cancer. 2015;62(7):1184-1189.
1886
haematologica | 2020; 105(7)